“ifm-therapeutics” Archives

in
Entry Author Date Location
Atlas Venture Raises $400M Fund to Seed Another New Set of Biotechs 06/05/20 Boston
Ventus Launches With $60M to Shine Light on Innate Immune System Drugs 05/06/20 Boston
Biotech Roundup: Drug Pricing Promises, Bone Disease Data, IPO Plans & More 01/10/20 National
Bio Roundup: Biogen at CTAD, Sage’s Stumble, Astellas’s $3B Offer & More 12/06/19 National
IFM Lands $55.5M to Launch NewCo Quattro and Discovery Incubator 12/02/19 Boston
Bio Roundup: Award Winners, Lung Data, Dems on Drug Pricing & More 09/13/19 National
The Winners of the 2019 Xconomy Awards Boston Are… 09/12/19 Boston
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone 09/06/19 National
Novartis & IFM Team Up Again, With Buyout Option for Autoimmune R&D 09/05/19 Boston
Novartis Adds Inflammation Drugs to Pipeline with Deal for IFM Tre 04/01/19 Boston
Harvard Spinout 28-7 Launches with $65M for MicroRNA Cancer Drugs 09/06/18 Boston
New Faces, Big Impact: Meet the Finalists For Xconomy’s Newcomer Award 08/07/18 Boston
The 2018 Xconomy Awards Finalists Are… 06/28/18 Boston
The Revolution in Inflammation Drug Development 05/15/18 Boston
Bristol-Myers Bets Nearly $2B on Nektar for an Immunotherapy Boost 02/14/18 New York
With $25M, Torque Aims for a More Targeted Cell Therapy for Cancer 11/14/17 Boston
Last Chance to Save on Boston’s Life Science Disruptors 09/20/17 Boston
Bio Roundup: RNAi Drama, Immunotherapy Data, Lasker Winners & More 09/08/17 National
Catch Dragonfly, IFM, Tesaro at “Disruptors” on Sept. 28 09/05/17 Boston
Biotech Roundup: CRISPR’s 1st Trial, IPO Insiders, Zika & More 06/24/16 National
IFM Therapeutics Receives $27,000,000 Series A Round 06/23/16 Boston
Atlas, Novartis Put $27M Into IFM to Battle Cancer, Autoimmune Diseases 06/22/16 Boston
Page 1 of 1